Stock Track | Zevra Therapeutics Plunges 5.76% Pre-Market Following Q3 Revenue Miss Despite Narrower Loss

Stock Track11-06

Shares of Zevra Therapeutics (ZVRA) tumbled 5.76% in pre-market trading on Thursday following the release of the company's third-quarter 2025 financial results. Despite reporting a narrower loss than expected, the biopharmaceutical firm fell short of revenue estimates, disappointing investors.

Zevra reported quarterly revenue of $26.06 million, marking a substantial 605.4% increase from the same period last year. However, this figure missed the average analyst expectation of $26.63 million. The company's flagship product, MIPLYFFA, contributed significantly to the revenue growth, bringing in $22.4 million for the treatment of Niemann-Pick disease type C.

On a positive note, Zevra posted a narrower-than-expected loss of 1 cent per share, beating the consensus estimate of a 4-cent loss. The company's net loss for the quarter stood at $544,000, a considerable improvement from the previous year. Despite these mixed results, the pre-market stock plunge suggests investors are focusing more on the revenue miss and potential growth concerns. Additionally, Zevra announced it is scaling back sales efforts for OLPRUVA due to limited market access, which may be contributing to the negative sentiment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135891693?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 17:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135891693","market":"nz","top_or_hot":-1,"title":"Stock Track | Zevra Therapeutics Plunges 5.76% Pre-Market Following Q3 Revenue Miss Despite Narrower Loss","media":"Stock Track","content":"<p>Shares of Zevra Therapeutics (ZVRA) tumbled 5.76% in pre-market trading on Thursday following the release of the company's third-quarter 2025 financial results. Despite reporting a narrower loss than expected, the biopharmaceutical firm fell short of revenue estimates, disappointing investors.</p>\n\n<p>Zevra reported quarterly revenue of $26.06 million, marking a substantial 605.4% increase from the same period last year. However, this figure missed the average analyst expectation of $26.63 million. The company's flagship product, MIPLYFFA, contributed significantly to the revenue growth, bringing in $22.4 million for the treatment of Niemann-Pick disease type C.</p>\n\n<p>On a positive note, Zevra posted a narrower-than-expected loss of 1 cent per share, beating the consensus estimate of a 4-cent loss. The company's net loss for the quarter stood at $544,000, a considerable improvement from the previous year. Despite these mixed results, the pre-market stock plunge suggests investors are focusing more on the revenue miss and potential growth concerns. Additionally, Zevra announced it is scaling back sales efforts for OLPRUVA due to limited market access, which may be contributing to the negative sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Zevra Therapeutics Plunges 5.76% Pre-Market Following Q3 Revenue Miss Despite Narrower Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Zevra Therapeutics Plunges 5.76% Pre-Market Following Q3 Revenue Miss Despite Narrower Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 17:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Zevra Therapeutics (ZVRA) tumbled 5.76% in pre-market trading on Thursday following the release of the company's third-quarter 2025 financial results. Despite reporting a narrower loss than expected, the biopharmaceutical firm fell short of revenue estimates, disappointing investors.</p>\n\n<p>Zevra reported quarterly revenue of $26.06 million, marking a substantial 605.4% increase from the same period last year. However, this figure missed the average analyst expectation of $26.63 million. The company's flagship product, MIPLYFFA, contributed significantly to the revenue growth, bringing in $22.4 million for the treatment of Niemann-Pick disease type C.</p>\n\n<p>On a positive note, Zevra posted a narrower-than-expected loss of 1 cent per share, beating the consensus estimate of a 4-cent loss. The company's net loss for the quarter stood at $544,000, a considerable improvement from the previous year. Despite these mixed results, the pre-market stock plunge suggests investors are focusing more on the revenue miss and potential growth concerns. Additionally, Zevra announced it is scaling back sales efforts for OLPRUVA due to limited market access, which may be contributing to the negative sentiment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZVRA","symbol_name":"Zevra Therapeutics","start_time":0,"source_url":"","article_id":"1135891693","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135891693","pubTimestamp":1762420702,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Zevra Therapeutics (ZVRA) tumbled 5.76% in pre-market trading on Thursday following the release of the company's third-quarter 2025 financial results. Despite reporting a narrower loss than...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZVRA":"Zevra Therapeutics"},"translate_title":"股票追踪|Zevra Therapeutics尽管亏损收窄，但第三季度营收未达预期，盘前暴跌5.76%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZVRA":1},"content_text":"Shares of Zevra Therapeutics (ZVRA) tumbled 5.76% in pre-market trading on Thursday following the release of the company's third-quarter 2025 financial results. Despite reporting a narrower loss than expected, the biopharmaceutical firm fell short of revenue estimates, disappointing investors.\nZevra reported quarterly revenue of $26.06 million, marking a substantial 605.4% increase from the same period last year. However, this figure missed the average analyst expectation of $26.63 million. The company's flagship product, MIPLYFFA, contributed significantly to the revenue growth, bringing in $22.4 million for the treatment of Niemann-Pick disease type C.\nOn a positive note, Zevra posted a narrower-than-expected loss of 1 cent per share, beating the consensus estimate of a 4-cent loss. The company's net loss for the quarter stood at $544,000, a considerable improvement from the previous year. Despite these mixed results, the pre-market stock plunge suggests investors are focusing more on the revenue miss and potential growth concerns. Additionally, Zevra announced it is scaling back sales efforts for OLPRUVA due to limited market access, which may be contributing to the negative sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135891693","isCrawlerRequest":true}